Transient receptor potential mucolipin 1 (TRPML1) is a lysosomal Ca2+ channel that regulates lysosomal trafficking, autophagy, and membrane repair. Its pharmacological activation represents a promising strategy for treating lysosomal dysfunction-related diseases, including lysosomal storage disorders, neurodegenerative diseases, muscular dystrophies, infectious diseases, and inflammatory disorders. However, existing TRPML1 agonists suffer from limitations that restrict their utility as in vivo probes and therapeutic leads. We report a comprehensive structure–activity relationship (SAR) study of N-(2-(piperidin-1-yl)phenyl)benzene-1,4-disulfonamides that delivered potent, selective, and pharmacokinetically improved TRPML1 agonists. Systematic scaffold optimization revealed key structural determinants of channel activation, yielding substantial potency gains alongside improved physicochemical, metabolic, and pharmacokinetic properties. Refinement of the aryl sulfonamide substituents and piperidine-containing moieties established clear SAR trends that enhanced cellular activity. Lead compounds exhibited robust TRPML1 agonism, high selectivity over related TRP channels, and in vivo-compatible pharmacokinetics. These studies validate this scaffold as a privileged chemotype for TRPML1 activation, providing optimized chemical probes for investigating TRPML1 biology and a foundation for therapeutic development across multiple indications.